Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
AstraZeneca
Teva
Healthtrust
Covington
Deloitte
Medtronic
Boehringer Ingelheim
McKinsey
Novartis

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,852,636

« Back to Dashboard

Which drugs does patent 8,852,636 protect, and when does it expire?

Patent 8,852,636 protects VIMOVO and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.
Summary for Patent: 8,852,636
Title:Pharmaceutical compositions for the coordinated delivery of NSAIDs
Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Inventor(s): Plachetka; John R. (Chapel Hill, NC)
Assignee: Pozen Inc. (Chapel Hill, NC)
Application Number:14/045,156
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 8,852,636

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 AB RX Yes No ➤ Sign Up ➤ Sign Up Y RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,852,636

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,926,907 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
8,858,996 Pharmaceutical compositions for the coordinated delivery of NSAIDS ➤ Sign Up
9,345,695 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
9,801,824 Method for delivering a pharmaceutical composition to patient in need thereof ➤ Sign Up
8,865,190 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
9,198,888 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
9,364,439 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
9,220,698 Method for delivering a pharmaceutical composition to patient in need thereof ➤ Sign Up
9,161,920 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
8,206,741 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,852,636

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Tunisia 2011000096 ➤ Sign Up
Portugal 1411900 ➤ Sign Up
Norway 2013014 ➤ Sign Up
Norway 333836 ➤ Sign Up
Norway 20035275 ➤ Sign Up
Mexico 2011002515 ➤ Sign Up
Mexico PA03011017 ➤ Sign Up
Morocco 32692 ➤ Sign Up
Luxembourg 91858 ➤ Sign Up
South Korea 20110079641 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
UBS
QuintilesIMS
Express Scripts
Deloitte
Mallinckrodt
Cantor Fitzgerald
Boehringer Ingelheim
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot